


World Journal of *Clinical Infectious Diseases*

World J Clin Infect Dis 2014 August 25; 4(3): 9-15



Editorial Board

2011-2015

The World Journal of Clinical Infectious Diseases Editorial Board consists of 291 members, representing a team of worldwide experts in infectious diseases. They are from 56 countries, including Argentina (5), Australia (8), Austria (3), Bangladesh (1), Belgium (2), Bosnia and Herzegovina (1), Brazil (6), Brunei Darussalam (1), Bulgaria (1), Cameroon (1), Canada (7), China (18), Colombia (1), Costa Rica (1), Cuba (1), Denmark (2), Egypt (1), Finland (1), France (11), Germany (4), Greece (8), Hungary (6), India (14), Indonesia (1), Iran (5), Israel (10), Italy (19), Japan (4), Jordan (1), Kosovo (1), Kuwait (1), Lebanon (3), Lithuania (1), Malawi (1), Mexico (5), Morocco (2), Netherlands (4), Nigeria (1), Pakistan (2), Peru (1), Philippines (1), Portugal (5), Russia (1), Saudi Arabia (2), Singapore (3), South Africa (2), South Korea (6), Spain (24), Switzerland (2), Tanzania (1), Thailand (4), Tunisia (1), Turkey (4), United Kingdom (9), United States (59), and Venezuela (1).

EDITORS-IN-CHIEF

Shyam Sundar, *Varanasi*
Lihua Xiao, *Atlanta*

GUEST EDITORIAL BOARD MEMBERS

Huan-Tsung Chang, *Taipei*
Jia-Ming Chang, *Taipei*
Kuo-Chin Huang, *Chiayi*
Wei-Chen Lee, *Taoyuan*
Hsiu-Jung Lo, *Miaoli*
Jin-Town Wang, *Taipei*
Deng-Chyang Wu, *Kaohsiung*
Jiunn-Jong Wu, *Tainan*

MEMBERS OF THE EDITORIAL BOARD



Argentina

Sergio Angel, *Chascomus*
Luis Adrian Diaz, *Cordoba*
Gustavo Daniel Lopardo, *Buenos Aires*
Emilio L Malchiodi, *Buenos Aires*
Victor D Rosenthal, *Buenos Aires*



Australia

Thea van de Mortel, *Lismore*
David Llewellyn Gordon, *Bedford Park*
Asad Khan, *Brisbane*
Ruiting Lan, *Sydney*
John McBride, *Cairns*
David Leslie Paterson, *Brisbane*
Nitin K Saksena, *Sydney*
Andrew Slack, *Brisbane*



Austria

Ojan Assadian, *Vienna*
Christian Joukhadar, *Vienna*
Bernhard Resch, *Graz*



Bangladesh

Harunor Rashid, *Cox's Bazar*



Belgium

Mickael Aoun, *Bruxelles*
Paul M Tulkens, *Brussels*



Bosnia and Herzegovina

Selma Uzunovic, *Zenica*



Brazil

Jane Costa, *Rio de Janeiro*
Pedro Alves d'Azevedo, *Sao Paulo*
Gerly Anne de Castro Brito, *Fortaleza*
RL Dantas Machado, *Sao Paulo*
Leandro R Rodrigues Perez, *Porto Alegre*
M de Nazare Correia Soeiro, *Rio de Janeiro*



Brunei Darussalam

Vui Heng Chong, *Bandar Seri Begawan*



Bulgaria

Iva Christova, *Sofia*



Cameroon

Richard Njouom, *Yaounde*



Canada

Aranka Anema, *Vancouver*
Peter C Coyte, *Toronto*
Pavel Gershkovich, *Vancouver*
Marcelo Gottschalk, *Quebec*
Marina Ulanova, *Thunder Bay*
Jude Uzonna, *Winnipeg*
Jun Wang, *Halifax*



China

Tian-Hua Huang, *Shantou*
Xi-Tai Huang, *Tianjin*
Dong-Ming Li, *Beijing*
Xin-Yong Liu, *Jinan*
Wu-Bin Pan, *Taichang*
Kai Wang, *Jinan*
Patrick Chiu Yat Woo, *Hong Kong*
Yong-Feng Yang, *Nanjing*
Chi-Yu Zhang, *Zhenjiang*
Li-Juan Zhang, *Beijing*



Colombia

Jorge Enrique Gomez-Marin, *Armenia*

**Costa Rica**

Adriano Arguedas, *San José*

**Cuba**

Maria G Guzman, *Havana*

**Denmark**

Janne Kudsk Klitgaard, *Odense*
Henrik Torkil Westh, *Hvidovre*

**Egypt**

Olfat Shaker, *Cairo*

**Finland**

Jari Timo Juhani Nuutila, *Turku*

**France**

Hassane Adakal, *Burkina Faso*
Pascal Bigey, *Paris*
Philippe Brouqui, *Marseille*
Christophe Chevillard, *Marseille*
Raphaelé Girard, *Pierre Bénite*
Vincent Pascal Jarlier, *Paris*
Sandrine Marquet, *Marseille*
Vayssier-Taussat Muriel, *Maisons-Alfort*
Thierry Naas, *Le Kremlin-Bicetre*
Saad Nseir, *Lille*
Philippe Seguin, *Rennes*

**Germany**

Stefan Borgmann, *Ingolstadt*
Georg Harter, *Ulm*
Matthias Imohl, *Aachen*
Kurt G Naber, *Straubing*

**Greece**

Apostolos Beloukas, *Athens*
Alex P Betrosian, *Athens*
George L Daikos, *Athens*
Helena Maltezou, *Athens*
Argyris S Michalopoulos, *Athens*
Maria Moschovi, *Athens*
George Petrikkos, *Athens*
Athanasios Tragiannidis, *Thessaloniki*

**Hungary**

Laszlo Galgoczy, *Szeged*
Viktor Muller, *Budapest*
Ferenc Orosz, *Budapest*
Ferenc Rozgonyi, *Budapest*
Jozsef Soki, *Szeged*

Dezso Peter Virok, *Szeged*

**India**

Ritesh Agarwal, *Chandigarh*
Syed Imteyaz Alam, *Gwalior*
Atmaram Hari Bandivdekar, *Mumbai*
Runu Chakravarty, *Kolkata*
Dipshikha Chakravortty, *Bangalore*
Sanjay Chhibber, *Chandigarh*
BN Harish, *Pondicherry*
Triveni Krishnan, *Kolkata*
Rashmi Kumar, *Lucknow*
Mohammad Owais, *Aligarh*
Banwarilal Sarkar, *Kolkata*
Mamta Chawla Sarkar, *Kolkata*
Akashdeep Singh, *Ludhiana*

**Indonesia**

Jeanne Adiwinata Pawitan, *Jakarta*

**Iran**

Parissa Farnia, *Tehran*
Seyed Mohammad Jazayeri, *Tehran*
Morteza Pourahmad, *Jahrom*
Mohammad Reza Pourshafie, *Tehran*
Mohammad Hossein Salari, *Tehran*

**Israel**

Jacob Amir, *Petach Tikvah*
Shai Ashkenazi, *Petach Tikva*
Gadi Borkow, *Gibton*
Raul Colodner, *Afula*
Jacob Moran Gilad, *Jerusalem*
Noah Isakov, *Beer Sheva*
Michal Mandelboim, *Hashomer*
Shifra Shvarts, *Omer*
Oshri Wasserzug, *Tel-Aviv*
Pablo Victor Yagupsky, *Beer-Sheva*

**Italy**

Giuseppe Barbaro, *Rome*
Paolo Bonilauri, *Reggio Emilia*
Guido Calleri, *Torino*
Mario Cruciani, *Verona*
Marco Falcone, *Rome*
Antonio Fasanella, *Foggia*
Daniele Focosi, *Pisa*
Delia Goletti, *Rome*
Guido Grandi, *Siena*
Fabio Grizzi, *Rozzano*
Giuseppe Ippolito, *Rome*
Roberto Manfredi, *Bologna*
Claudio M Mastroianni, *Rome*
Ivano Mezzaroma, *Rome*
Giuseppe Micali, *Catania*
Antonella d'Arminio Monforte, *Milano*
Annamaria Passantino, *Messina*
Mariagrazia Perilli, *L'Aquila*
Patrizia Pontisso, *Padova*

**Japan**

Masashi Emoto, *Maebashi*
Toshi Nagata, *Hamamatsu*
Ryohei Yamasaki, *Tottori*
Shin-Ichi Yokota, *Sapporo*

**Jordan**

Asem A Shehabi, *Amman*

**Kosovo**

Lul Raka, *Prishtina*

**Kuwait**

Willias Masocha, *Safat*

**Lebanon**

Ziad Daoud, *Beirut*
Ghassan M Matar, *Beirut*
Sami Ramia, *Beirut*

**Lithuania**

Gazim Bizanov, *Vilnius*

**Malawi**

Adamson Sinjani Muula, *Blantyre*

**Mexico**

Agnes Fleury, *Mexico*
Guadalupe Garcia-Elorriaga, *Mexico*
Alejandro E Macias, *Mexico*
Mussaret Zaidi, *Merida*
Roberto Zenteno-Cuevas, *Veracruz*

**Morocco**

Redouane Abouqal, *Rabat*
Ezzikouri Sayeh, *Casablanca*

**Netherlands**

Aldert Bart, *Amsterdam*
John Hays, *Rotterdam*
Nisar Ahmed Khan, *Rotterdam*
Rogier Louwen, *Rotterdam*

**Nigeria**

Samuel Sunday Taiwo, *Osogbo*



Pakistan

Muhammad Idrees, *Lahore*
Muhammad Mukhtar, *Bahawalpur*



Peru

Salim Mohanna, *Lima*



Philippines

Vicente Y Belizario, *Ermita Manila*



Portugal

Ricardo Araujo, *Porto*
Manuela Canica, *Lisbon*
Francisco Esteves, *Lisbon*
Fernando Rodrigues, *Braga*
Nuno Taveira, *Lisbon*



Russia

Alexander M Shestopalov, *Koltsovo*



Saudi Arabia

Jaffar A Al-Tawfiq, *Dhahran*
Atef M Shibl, *Riyadh*



Singapore

Yee Sin Leo, *Singapore*
Laurent Claude Stephane Renia, *Singapore*
Richard J Sugrue, *Singapore*



South Africa

Carolina H Pohl-Albertyn, *Bloemfontein*
Natasha Potgieter, *Louis Trichardt*



South Korea

Chong Cho, *Seoul*
Sang Ho Choi, *Seoul*
Ju-Young Chung, *Seoul*
Jung Mogg Kim, *Seoul*
Kyongmin Kim, *Suwon*
Sang Hee Lee, *Yongin*



Spain

Alberto Arnedo-Pena, *Castellon*
Alfredo Berzal-Herranz, *Granada*
Vicente Brito, *Alicante*

Enrique Calderon, *Seville*

Rafael Canton, *Madrid*

Jose M Cuevas, *Valencia*

Laila Darwich, *Cerdanyola del Valles*

Adela Gonzalez de la Campa, *Madrid*

Pere Domingo, *Barcelona*

Tahia D Fernandez, *Malaga*

Lucia Gallego, *Leioa*

Luis Ignacio Gonzalez-Granado, *Madrid*

Bruno Gonzalez-Zorn, *Madrid*

Eduardo Lopez-Collazo, *Madrid*

Miguel Marcos, *Salamanca*

Antonio Torres Marti, *Barcelona*

Andres Moya, *Valencia*

Rafael Najera, *Madrid*

Maria Mercedes Nogueras-Mas, *Sabadell*

Jose A Oteo, *Logrono*

Pilar Perez-Romero, *Sevilla*

Ruth Gil Raka, *Madrid*

Eduardo Reyes, *Madrid*

Francisco Soriano, *Madrid*



Switzerland

Stephen Hawser, *Epalinges*
Andrew Hemphill, *Bern*



Tanzania

John Peter Andrea Lusingu, *Tanga*



Thailand

Kosum Chansiri, *Bangkok*
Subsai Kongsangdao, *Bangkok*
Niwat Maneeakarn, *Chiang Mai*
Viroj Wiwanitkit, *Bangkok*



Tunisia

Aouni Mahjoub, *Monastir*



Turkey

Oguz Karabay, *Sakarya*
Uner Kayabas, *Malatya*
Gokhan Metan, *Kayseri*
Oral Oncul, *Istanbul*



United Kingdom

Zainab Al-Doori, *Glasgow*
David Carmena, *London*
Ronald Anthony Dixon, *Lincoln*
Vanya Alasdair Ivan Andre Gant, *London*
Robin Goodwin, *London*
Andrew Cunliffe Hayward, *London*
Laura Anne Hughes, *Neston*
Michele Esther Murdoch, *Herts*
Craig William Roberts, *Glasgow*



United States

Majdi N Al-Hasan, *Lexington*
Ibne KM Ali, *Charlottesville*
Hossam M Ashour, *Detroit*
Joseph Urban Becker, *Palo Alto*
M Eric Benbow, *Dayton*
Eliahu Bishburg, *Newark*
Luz P Blanco, *Ann Arbor*
Robert Bucki, *Philadelphia*
Steven Dale Burdette, *Dayton*
Archana Chatterjee, *Omaha*
Pai-Lien Chen, *Durham*
Pawel S Ciborowski, *Omaha*
Michael Cynamon, *Syracuse*
Siddhartha Das, *El Paso*
Ralph J DiClemente, *Atlanta*
Noton Kumar Dutta, *Baltimore*
Garth D Ehrlich, *Pittsburgh*
Michael S Firstenberg, *Columbus*
Walter A Hall, *Syracuse*
Yongqun He, *Ann Arbor*
Brenda Lorraine Helms, *Plano*
Joseph U Igietseme, *Atlanta*
Mohammad Khalid Ijaz, *Montvale*
Suresh G Joshi, *Philadelphia*
Thomas F Kresina, *Rockville*
Alain B Labrique, *Baltimore*
Shenghan Lai, *Baltimore*
Benfang Lei, *Bozeman*
Jeff G Leid, *Flagstaff*
Vladimir Leonitiev, *St. Louis*
Andrea Lisco, *Bethesda*
James M McMahon, *Rochester*
Geraldine M McQuillan, *Hyattsville*
Lawrence F Muscarella, *Ivyland*
Daniel Musher, *Houston*
Stella Nowicki, *Nashville*
M Jacques Nsuami, *New Orleans*
Phillipe N Nyambi, *New York*
Raymund Rabe Razonable, *Rochester*
Anand Reddi, *Denver*
Michael Switow Saag, *Birmingham*
Danny J Schust, *Columbia*
William R Schwan, *La Crosse*
Richard A Slayden, *Fort Collins*
Theodore J Standiford, *Ann Arbor*
William M Switzer, *Atlanta*
Ashutosh Tamhane, *Birmingham*
Giorgio E Tarchini, *Weston*
Carmen Taype, *New York*
Barbara Van Der Pol, *Bloomington*
Jose Antonio Vazquez, *Detroit*
Fernando Villalta, *Nashville*
Haider J Warraich, *Boston*
Xianfu Wu, *Atlanta*
Genyan Yang, *Atlanta*
Frank X Yang, *Indianapolis*
Hong Zhang, *Rockville*
Lyna Zhang, *Atlanta*



Venezuela

Alfonso J Rodriguez-Morales, *Caracas*



MINIREVIEWS

9

Prosthetic joint infections-a clinico-microbiological perspective: Review article

Nair PK, Bhat VG, Vaz MS

Contents

World Journal of Clinical Infectious Diseases
Volume 4 Number 3 August 25, 2014

APPENDIX I-V Instructions to authors

ABOUT COVER Editorial Board Member of *World Journal of Clinical Infectious Diseases*, Jose Antonio Vazquez, Senior Staff, Professor of Medicine, Henry Ford Hospital, Division of Infectious Diseases, 2799 West Grand Boulevard, CFP-202, Detroit, MI 48202, United States

AIM AND SCOPE

World Journal of Clinical Infectious Diseases (*World J Clin Infect Dis*, *WJCID*, online ISSN 2220-3176, DOI: 10.5495) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJCID will focus on a broad spectrum of topics on infectious diseases that will cover epidemiology, immune-pathogenesis, genetic factors, host susceptibility to infection, vector control, novel approaches of treatment, molecular diagnostic and vaccines. It will provide a common stage to share the visions, new approaches, most advanced techniques, and to discuss research problems that will help everyone working in the field of various infections to exchange their views and to improve public health. *WJCID* will also focus on broad range of infections like opportunistic infections, zoonotic infections, tropical and neglected tropical diseases, emerging infections, *etc.* and following topics related to these issues: (1) Causative agents discussing various pathogens; (2) Vectors and Mode of transmission; (3) Host-pathogen interaction and immune-pathogenesis of the disease; (4) Epidemiology of the infection and vector control strategies; (5) Genetic factors covering both host and pathogen; (6) Molecular diagnostic techniques vaccines; and (7) Recent advances in cell tissue culture, lab techniques, *etc.* Various other related fields like medical microbiology, pharmacology of herbs, bioinformatics, *etc.* will be included.

We encourage authors to submit their manuscripts to *WJCID*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING *World Journal of Clinical Infectious Diseases* is now indexed in Digital Object Identifier.

FLYLEAF I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Su-Qing Liu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Xue-Mei Gong*
Proofing Editorial Office Director: *Xiu-Xia Song*

NAME OF JOURNAL
World Journal of Clinical Infectious Diseases

ISSN
ISSN 2220-3176 (online)

LAUNCH DATE
December 30, 2011

FREQUENCY
Quarterly

EDITORS-IN-CHIEF
Shyam Sundar, MD, FRCP (London), FAMS, FNA Sc, FASc, FNA, Professor, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India

Lihua Xiao, DVM, PhD, Senior Scientist, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Bldg 23, Rm 9-168, MS D66, 1600 Clifton

Rd, Atlanta, GA 30333, United States

EDITORIAL OFFICE
Jin-Lei Wang, Director
Xiu-Xia Song, Vice Director
World Journal of Clinical Infectious Diseases
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381891
Fax: +86-10-85381893
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.wjgnet.com/esp/helpdesk.aspx>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
8226 Regency Drive,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.wjgnet.com/esp/helpdesk.aspx>
<http://www.wjgnet.com>

PUBLICATION DATE
August 25, 2014

COPYRIGHT
© 2014 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at http://www.wjgnet.com/2220-3176/g_info_20100722180909.htm.

ONLINE SUBMISSION
<http://www.wjgnet.com/esp/>

Prosthetic joint infections-a clinico-microbiological perspective: Review article

Pravin K Nair, Vivek G Bhat, Michelle S Vaz

Pravin K Nair, Michelle S Vaz, Department of Microbiology, Holy Spirit Hospital, Andheri (E), Mumbai 400093, India
Vivek G Bhat, Department of Microbiology, ACTREC-Tata Memorial Center, Navi Mumbai 410210, India

Author contributions: All the authors contributed equally to the work in literature survey and writing of the paper.

Correspondence to: Vivek G Bhat, MD, Associate Professor-Microbiology, Advanced Centre for Treatment, Research and Education in Cancer, Department of Microbiology, ACTREC-Tata Memorial Centre, Navi Mumbai 410210, India. vivekbhat2005@yahoo.com

Telephone: +91-22-27405093 Fax: +91-22-27405061

Received: June 24, 2014 Revised: July 21, 2014

Accepted: August 20, 2014

Published online: August 25, 2014

Abstract

Prosthetic joint infections (PJIs), although not very common, currently pose a very significant threat since they are associated with severe complications, high morbidity rates and substantial costs. PJIs are most commonly caused by *Staphylococcus aureus* and coagulase-negative staphylococci. The diagnosis of implant-associated infections is very challenging since no single routinely used laboratory or clinical test has been shown to demonstrate adequate results with respect to sensitivity, specificity and accuracy. In most cases, a sum of clinical signs and symptoms, histopathology, blood tests, radiography, bone scans and microbiological testing is considered to arrive at an accurate diagnosis. Treatment of PJIs is also very difficult since most of the infections are caused by biofilm-producing microorganisms which are significantly more resistant to the hosts natural defense mechanisms and antibiotic treatment. For successful management, a combination of both antibiotic and surgical treatment is most often required, and early diagnosis is of the utmost importance. Thus, a multidisciplinary approach is potentially the best option in dealing with PJI, and should include the involvement of microbiologists,

orthopedic specialists, clinicians, pathologists and radiologists in order to improve decision-making processes and ensure overall success. The following review aims at briefly outlining the microbiology, diagnostic and treatment options, and preventive measures associated with such infections.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Prosthetic joint infections; Biofilms; Diagnosis; Antimicrobial therapy; Surgical treatment

Core tip: Prosthetic joint infections (PJIs), although uncommon, may be associated with significant complications and morbidity. Staphylococci are among the most commonly involved organisms. Diagnosis may be challenging in spite of the availability of various laboratory and radiological tests. Treatment too, is often difficult because most infections are caused by biofilm producing organisms. A combination of prudent surgical intervention and specific antibiotic treatment is the key to a successful management. Thus, a multidisciplinary approach is the best option in dealing with PJI, and should involve a team of orthopedic specialists, clinicians, pathologists, radiologists and microbiologists to ensure best outcomes.

Nair PK, Bhat VG, Vaz MS. Prosthetic joint infections-a clinico-microbiological perspective: Review article. *World J Clin Infect Dis* 2014; 4(3): 9-15 Available from: URL: <http://www.wjgnet.com/2220-3176/full/v4/i3/9.htm> DOI: <http://dx.doi.org/10.5495/wjcid.v4.i3.9>

INTRODUCTION

The use of prosthetic material in orthopedic surgery has become common in recent times, due to its high success rate with total joint replacement and the management of

fractures. Whilst not very common, prosthetic joint infections (PJIs) pose a very significant threat, considering the number of total joint replacements undertaken each year and the millions of people who currently have indwelling prostheses^[1]. These infections are associated with severe complications, high morbidity rates and substantial costs^[2]. PJIs linked with total hip and knee arthroplasty occur at an incidence rate of 1.5%-2.5% in the case of primary interventions. However after revision procedures, rates as high as 2%-20% have also been reported^[3].

PJIs are generally classified as per their time of onset after surgery. In the case of early PJI, the first signs and symptoms appear in the initial 3 mo post-surgery. However, there are some authors who are in disagreement with the prior mentioned timeframe, and limit the same to the first 2 to 4 wk. Similarly, in delayed manifestations initial infection signs and symptoms occur anywhere between 3 mo and 2 years post-surgery; and late manifestations, > 2 years post-surgery^[4].

RISK FACTORS

Certain groups of individuals can be considered to be at a higher risk of prostheses infections when compared to others. These include patients those who suffer from rheumatoid arthritis, diabetes mellitus, psoriasis, *etc.*; and those who are immunocompromised, aged, infected with human immunodeficiency virus, have had long-term urinary catheterization, and/or have poor nutritional status^[1,3]. Other risk factors include smoking, obesity, corticosteroids, burns, liver disease, neoplasia, chemotherapy and radiotherapy^[2]. In cases where PJI patients possess more than one implant, there is a significant risk of a subsequent infection developing in the other prostheses present at the time of infection^[5].

Mortality associated with PJIs in the case of elderly patients is as high as 8%^[6]. In a study conducted by Grammatico-Guillon *et al*^[7] in 2012, bone and joint infections were found to be not only age related, but were also found to be higher in males. This parallels the general trend of Rheumatoid Arthritis in the same group of individuals. The study also showed that the most frequent comorbidities associated with such infections are diabetes, ulcer sores and peripheral vascular disorders^[7].

PATHOGENESIS

The development of a PJI is the result of an interaction between the patient, pathogen, environment, intervention and wound factors^[2]. Implanted devices are known to possess a substantial risk of bacterial and fungal colonization. Studies have shown that having a foreign body present significantly decreases the minimal infecting dose of *Staphylococcus aureus* (*S. aureus*) causing a permanent abscess. In an experiment involving animal models, it has also been shown that as low as 100 colony-forming units of *S. aureus* can be sufficient to infect 95% of subcutaneous implants present^[8].

Host defense in the vicinity of implant region also plays a significant role in the emergence of PJIs. The most significant microorganisms responsible for causing these infections are *S. aureus* and coagulase-negative staphylococci (CoNS). It has been found that even few of these skin-derived microorganisms are capable of colonizing implants during surgery, since granulocytes surrounding the implant are rendered incapable of clearing bacteria. This is because granulocytes that accumulate around the implant become partially degranulated due to the introduction of a non-phagocytosable foreign object, and superoxide production is also decreased. After a biofilm has been established, even fully functional granulocytes cannot clear adherent staphylococci^[8].

PJIs occur usually by one of two routes, the first being introduced at or about the time of operation. This may be caused by wound sepsis post-operatively, by infected haematomas, or by operative contamination. Early infections may be either due to a single organism (*e.g.*, *S. aureus*) or may be polymicrobial in nature. PJIs caused by CoNS tend to present themselves relatively late (even after a year in some cases). However, even these infections are caused at the time of operation itself. The delayed presentation of such organisms is due to their low pathogenicity and tendency to produce biofilms, which allows them to stay sub clinical for considerable periods of time^[8,9]. The second route is by that of haematogenous spread. Any existing bacteraemia can lead to prosthetic material infection, although *S. aureus* is considered to be the most common cause. In cases where sinuses are present, PJIs may even involve a range of skin organisms, including Gram-negative, Gram-positive and anaerobic bacteria^[9].

MICROBIOLOGY

Prosthetic material provides an ideal environment in which many microorganisms can flourish^[10]. The most common bacterial agents responsible for close to 65% of all PJIs are *S. aureus* and *Staphylococcus epidermidis*. This is because these bacteria possess surface proteins that have adhesive properties, facilitating their initial colonization. These microorganisms have been reported in early as well as in late infections associated with total knee and total hip arthroplasty, and are commonly found to be methicillin resistant. Recently, Lee *et al*^[11] reported that not only is *S. aureus* responsible for causing PJIs, it may also be an independent risk factor that may be responsible for treatment failure. Other microorganisms such as streptococci, diphtheroids and enterococci have been found to be responsible for approximately 10% of PJIs each^[2,3].

Gram negative microorganisms are less common than Gram positives in PJIs. However, infections caused by them are far more complicated and require longer treatment^[12]. Polymicrobial infections have been found to occur usually in early PJIs^[13]. These, along with infections caused by unusual pathogens such as *Brucella* spp. and various mycobacteria; although not as common, have

also been reported. Anaerobic microbes are found usually only as a part of polymicrobial infections^[2]. In cases of tubercular PJIs, misdiagnosis proves to be a substantial risk owing to the low index of suspicion attributed to such infections. This could lead to a delay in correct diagnosis, with the risk of permanent damage due to a late treatment^[14]. PJIs are also caused by fungal agents like *Candida* and *Asperillus*^[15].

There are several PJI cases where the growth of microorganisms is absent from aerobic and anaerobic cultures of periprosthetic tissue samples^[3]. Such culture negativity is an important issue in the treatment of PJIs since negative cultures raise uncertainty in the diagnosis of infection and makes choosing the appropriate antibiotics very challenging^[16]. A study by Choi *et al*^[16] showed that the success rate of infection control in the case of culture negative infections is higher, suggesting that the culture negativity may not necessarily be a negative prognostic factor for treating prosthetic joint infections.

Microorganisms found in PJIs that are caused by haematogenous dissemination include Gram negative bacilli, enterococci and anaerobes from genitourinary and gastrointestinal tract procedures or infections; *Streptococci viridans*, *Peptococcus* spp. and *Peptostreptococcus* spp. from dentogingival processes and manipulations; and *Streptococcus* spp. from pyogenic skin infections^[3]. Few cases of PJIs caused by *Haemophilus parainfluenzae* have also been reported, most caused due to bacteraemia from dental origin^[17]. Recently, Bjerke-Kroll *et al*^[18] also reported *Streptococcus viridans* as a significant risk factor for transient bacteremia following dental extractions.

ROLE OF BIOFILMS

PJIs are characteristically caused by biofilm-forming bacteria. Biofilms can be defined as microorganisms possessing altered phenotypes that live together in a self-organized aggregate. This aggregate is embedded in an exopolymer saccharide matrix which is self-produced and allows the attachment of the biofilm to an external surface. Prosthesis colonization by biofilm-producing bacteria can occur during implantation or by haematogenous seeding. A variety of microorganisms are known to grow in biofilms, including *S. aureus* and CoNS, which are of particular importance in PJIs^[3]. The ability of microorganisms to form biofilms is a virulence factor^[8]. Biofilm microbes are considered to be around 10 to 1000 times less susceptible to antibiotics, especially cell wall targeting agents. It is also difficult to predict the pharmacodynamic parameters of antimicrobial agents against these microorganisms. Thus, drugs are often used in concentrations higher than would be otherwise required^[3].

There have been several postulations and investigations to explain the increased antimicrobial resistance associated with biofilm-producing bacteria. Although the extracellular matrix in biofilms does physically restrict antimicrobial agents to some extent, it does not seem to be the predominant mechanism conferring resistance. Some

bacteria enter a non-growing stationary state due to decreased nutrient and oxygen levels inside the biofilm. As a result, their susceptibility to antimicrobials is reduced given that their action is growth-dependent. Some bacteria also differentiate into phenotypically resistant states; while others have shown to exhibit gene expression that confers antimicrobial resistance which is biofilm-specific, but has no role in biofilm formation^[3].

DIAGNOSIS

PJIs currently have no universal definition. Most generally, a PJI is considered to be present when at least one of the forementioned criteria is fulfilled-evident purulence in the synovial fluid or around the prosthesis; presence of acute inflammation when periprosthetic tissue sections are histopathologically examined; sinus tract communication with the prosthesis; or when the same organism is found to be growing in repeated cultures of either synovial fluid, periprosthetic tissue or the implant itself^[19].

With the evaluation of patients suspected to have PJI, clinicians initially have to verify whether the dysfunction has been septic or aseptically caused. In some cases clinical diagnosis of PJIs is possible; however, laboratory testing is often required. On arriving at a satisfactory diagnosis, clinicians look to microbiological results for the identification of the underlying microbial cause, as well as to attain antimicrobial susceptibility levels so as to execute appropriate treatment. When a PJI is due to a virulent organism such as *S. aureus*, clinical symptoms like fever, effusion, warmth, erythema, and pain localized to the joint may occur. However, if the infection is caused due to low-virulence organisms like *P. acnes* or CoNS, pain and/or loosening of the prosthesis can take place without manifesting any further clinical signs. This leads to a challenging situation where the clinician cannot positively distinguish such an infection from aseptic arthroplasty failure^[19]. When a PJI is suspected, it is recommended to wait a minimum of 15 d post any antibiotic treatment before performing tests in order to decrease the rate of false negative results, following which pre-operative sampling is to be performed. If the results are positive, surgical and antibiotic management can be planned. In the case of fever and other nonspecific clinical symptoms, it is recommended to perform blood cultures for aerobic and anaerobic bacteria so that rapid probabilistic antibiotherapy can be initiated before considering surgery. Negative results do not rule out the possibility of an existing infection^[15].

In the diagnosis of PJIs, no single routine clinical or laboratory test is known to demonstrate ideal sensitivity, specificity and accuracy. Therefore, a sum of clinical signs and symptoms, blood tests, histopathology, radiography, bone scans and microbiological testing is collectively used to attain an accurate diagnosis^[3]. Blood tests are usually the first laboratory tests to be carried out. In the immediate postoperative period, C-reactive protein levels are found to be elevated and leucocytosis is ob-

served, which returns to normal within a few weeks^[2]. Thus repetitive measurements can be indicative of PJI, but these results are neither sensitive nor specific^[8]. In histopathological studies, tissue neutrophil levels are known to suggest infection. However, a generally accepted definition does not exist for acute inflammation. Several imaging techniques are employed to detect PJI. These include General Radiography, computed tomography, Ultrasonography, magnetic resonance imaging, Bone Scintigraphy with Technetium-99m-labelled Methylene Diphosphonate and Fluorodeoxyglucose positron emission tomography^[3,8].

MICROBIOLOGIC ANALYSIS

Preoperative specimens

This involves the testing of sinus tracts, superficial wounds, synovial fluid and preoperative tissue samples prior to any surgical revision procedure^[19]. However, cultures of superficial wounds, sinus tracts often represent microbial colonization which can be misleading, and therefore lack predictive value^[3,19]. Isolation of *S. aureus* from sinus tracts is considered to be predictive of the causative pathogen^[3].

Pre-operative culture of Aspirated Synovial fluid can be useful in the diagnosis of PJIs; especially in patients who have underlying inflammatory diseases, where routine Inflammatory markers may not very reliable^[3,19]. Synovial fluid cultures allow microorganism identification with a sensitivity of as high as 82%-94%, and a specificity of 94%-97%^[3]. Use of paediatric blood-culture bottles has been shown to improve sensitivity^[8]. However, reports of discordance between synovial fluid and intraoperative cultures, with rates of false-positives between 3% to 16% and false-negative results from 8% to 50%. It has been shown that the false-negative results can be attributed to the bactericidal effect of anesthetics, low bacterial loads in synovial fluid and presence of fastidious organisms. The instillation of normal saline into joints to aid aspiration may result in the dilution of the specimen bacterial load. Gomez *et al*^[19] in 2011 stated that preoperative tissue cultures do not suggest any advantage over synovial fluid cultures.

Intraoperative specimens

Periprosthetic tissue samples are commonly examined to detect infecting microorganisms in PJIs. Prior to sampling, it is imperative to discontinue any antimicrobial therapy for a period of at least 2 wk^[8]. Gram stains of periprosthetic tissues are rarely given any clinical importance due to their extremely low sensitivity that ranges from 0% to 30%. The sensitivity of bacterial detection from periprosthetic tissue cultures using conventional techniques is between 37% and 61%. This relatively low sensitivity may be attributed to the fact that the growth of the causative microorganisms is more so on the implant surface rather than in the surrounding tissue. To increase sensitivity, it is recommended that the evaluation of a minimum of five

specimens should be carried out^[20]. Some studies even suggest extending the incubation period for the cultures, and sonication of the tissue samples to disperse adherent bacteria^[3]. False-positive results are obtained from periprosthetic tissue cultures due to contamination during surgery, specimen transport, or specimen processing, these effect the specificity of results. Moreover, problems with specificity occur due to difficulties in establishing the clinical significance of common skin flora growth in intraoperative cultures^[20].

It's a well known fact that Swab cultures are less efficient as compared to tissue and synovial fluid culture samples, and should thus be avoided. They are more prone to contamination and have a high tendency to convey false-positive results. Anaerobes are most commonly isolated using blood culture bottles when compared to isolation from swab and tissue cultures^[20] thereby indicating loss of bacterial viability during transport that may be responsible for some false-negative culture results.

Removed implant or fragments

The growth of biofilm-forming bacteria may evade detection using periprosthetic tissue cultures^[20]. Since biofilms play a very important role in infections, implant cultures has been found to be superior as compared to tissue culture. Explanted foreign material is usually vortexed or sonicated before culturing. This detaches the biofilm-associated bacteria, leaving it liberated in the surrounding broth^[8]. Sonication has been used to diagnose infections of multiple medical device types, including orthopedic devices, breast implants, vascular grafts, cardiac devices, vascular catheters, and ureteral stents. Sonicate fluid has the advantage over periprosthetic tissue culture in having a shorter time to positivity^[20].

Other non-culture PJI diagnostic techniques

The serological detection of PJI-causing microorganisms involves the detection of antibodies against such organisms. This technique, although fairly simple to perform, lacks substantial specificity which may be attributed to low basal antibody titers that are often recorded against organisms like CoNS, since they are apart of normal human flora. Direct visualization of PJI-associated bacteria from sonication fluid, using immunofluorescence microscopy by means of pathogen-targeted antibodies, can also be used in the diagnosis of PJI. However this method lacks clarity and provides no evident advantage over conventional culture techniques. Molecular techniques, theoretically, have shown to exhibit very good potential in overcoming drawbacks associated with culture methods when it comes to biofilm-associated infections. Unfortunately, studies evaluating these methods are very limited and are often contradictory. The major disadvantages associated with the molecular diagnosis of PJIs are the inability of the technique to provide essential antimicrobial susceptibility results, and the incidence of false-positive results that occur. False-positive results may be caused by DNA from non-viable bacteria that may have

contaminated patient specimens and reagents; or caused by amplicon contamination^[20].

TREATMENT

Surgical intervention and antimicrobial therapy are the two main modes of treatment for the management of PJIs, which may even be initiated while awaiting microbiological results to avoid permanent joint cartilage damage^[10]. To achieve complete therapy success, a combination of both these methods is usually required, and early diagnosis is of the utmost importance^[8].

Antimicrobial therapy

There are no general standards for an ideal regimen and duration for the administration of antimicrobial agents in the treatment of PJIs^[3]. In the presence of a prosthetic device, growth recurrence is frequent. Therefore, as in treating tuberculosis cases, killing of all microorganisms is essential^[8].

A well-defined example of optimal antimicrobial therapy is the use of Rifampicin in staphylococcal implant infections^[8]. It has excellent efficacy against staphylococci in its stationary phase, exceeds minimum inhibitory concentrations (MICs) by a factor of about 10-100 at trough levels and can also be well absorbed orally^[3]. It also has proven *in vitro* activity in several clinical studies. Rifampin must always be used in combination with another antibiotic so as to prevent the emergence of resistance. When used synergistically, it has shown excellent activity against susceptible slow-growing and adherent staphylococci. Quinolones have been found to be excellent combination drugs owing to their good bioavailability, safety and activity^[8]. Ciprofloxacin is another drug that is commonly used in combination with Rifampicin. Several studies have demonstrated improved efficacy in favour of the rifampicin/ciprofloxacin combination as opposed to ciprofloxacin monotherapy, to be used in the treatment of staphylococcal infections associated with orthopaedic implant devices^[3]. Rifampicin can also be used with other antimicrobial agents like fusidic acid, cotrimoxazole, trimethoprim/sulfamethoxazole, linezolid and minocycline^[3,8]. However negative results have been reported when Rifampicin has been used with Levofloxacin orally^[3].

Staphylococci, both *S. aureus* and CoNS, have increasingly shown resistance to methicillin over the past few years; and Methicillin-resistant *S. aureus* (MRSA) infections have had a severe impact on PJIs. Patients with MRSA infections in periprosthetic tissue cultures have a higher probability of treatment failure as compared to those with methicillin-susceptible *S. aureus* infections. Also, patients with MRSA PJIs are prone to hospitalization for longer periods of time (median 15 d *vs* 10 d). Intravenous glycopeptides are primarily used to treat PJIs caused by methicillin-resistant Gram-positive bacteria. For MRSA infections postsurgery, continuous outpatient vancomycin perfusion has been used successfully. Prolonged administration of teicoplanin once daily has also appeared to be

relatively efficacious. Newer antibiotics like quinupristin/dalfopristin, linezolid, daptomycin and tigecycline are active against MRSA strains. Drugs like oritavancin, dalbavancin, faropenem and telavancin have shown promising results^[3]. Quinopristin/dalfopristin shows activity against *Enterococcus faecium* (including vancomycin-resistant strains) as well as *S. aureus* (including MRSA). In a study of 40 patients suffering from MRSA orthopaedic infections and who were put on Quinopristin/dalfopristin, clinical success was found in 78% and microbial eradication in 69% of the cases^[8]. However, side-effects and drug interactions has halted its use widely^[3].

Linezolid shows potential in the treatment of PJIs because of its bioavailability and antimicrobial spectrum. It possesses a very wide anti-Gram-positive bacterial spectrum, which includes all CoNS species. It also shows good diffusion in bone tissue. In an comparative study by Cobo *et al*^[21], 86% of patients treated with linezolid demonstrated clinical and microbiological cure. Unfortunately, toxicity associated with the drug is a matter of concern. Adverse effects like reversible myelo suppression, optic neuropathy and peripheral neuropathy are quite common with linezolid treatment. In most cases, optic neuropathies were resolved after linezolid stoppage, but peripheral neuropathies were found to be irreversible^[8].

Drugs like Daptomycin and Tigecycline make for attractive options in the treatment of PJIs^[3,8]. Daptomycin has rapid bactericidal activity against most Gram-positive microbes, including MRSA, Vancomycin-resistant *S. aureus*, and Vancomycin-resistant enterococci^[8]. Tigecycline is a novel glycylcycline antibiotic possessing a broad spectrum of activity. It has *in vitro* bacteriostatic activity against several Gram-positive, Gram-negative, anaerobic, atypical and antimicrobial-resistant bacteria. However, there is not enough available data for the application of these drugs in PJI management^[3].

Surgical treatment

The management of suspected PJIs mainly rests in the hands of orthopaedic surgeons since surgical procedures are most often required^[22]. Debridement is usually the first step in surgical treatment and involves the removal of any scar tissue, haematomas, devitalized tissue, and sinus tracts^[2]. This method has been found to have limited success (varying from 20%-60%); and prosthesis removal and replacement is frequently required^[2,23]. This however, may be attributed to the fact that debridement and implant retention has often been carried out on patients who have not entirely been suited to the procedure. Recently several algorithms have been published to aid in the selection process, and have been found to significantly increase the success rate of debridement procedures^[23]. One-stage or Direct Revision is sought to in patients for whom two staged operations would represent a substantial operative risk^[1]. It involves the replacement of an old prosthesis with a new one during the same surgical procedure^[8].

Two-stage (staged) Revision is the commonest surgi-

cal intervention in PJI management^[9]. Success rates of > 90% have been reported in several studies for the procedure, when 6 wk of antimicrobial treatment have been administered between the stages^[24]. Recently, Tsai *et al*^[25] reported that patients who have undergone two-stage revision are less prone to recurrent infections. The surgery is especially preferred in cases where resistant or difficult-to-eradicate microorganisms are involved like MRSA, enterococci, staphylococci, Multi drug-resistant *Pseudomonas aeruginosa* or fungi^[8]. In the first stage of the procedure, the prosthesis is removed along with carrying out a thorough debridement of all existing dead and infected tissue. The prosthesis is usually replaced by an antibiotic-loaded cement spacer in order to prevent joint space contracture that may occur between stage^[26]. Other antibiotics may also be administered systemically. In very few cases that involve an acute infection, the implant may be preserved. The second-stage of the procedure involves the insertion of a new prosthesis into the site previously made sterile, and is usually carried out about 8-12 wk after the first stage once all inflammatory markers have attained normal levels and wound healing is complete^[9].

Permanent removal of the prosthetic device is usually reserved for patients with a high risk of reinfection, like those with severe immunosuppression or those who are active intravenous drug users; or when no functional improvement is expected after reimplantation^[8]. Occasionally, in cases where the patient is not suitable for surgical procedures or for those who refuse operations, a long-term suppressive antibiotic regimen may be employed to suppress bacterial growth and to control symptoms^[1]. However, since this approach only controls clinical symptoms rather than actually curing PJI, the infection tends to relapse in most patients (> 80%) on discontinuing the antibiotics^[8].

PREVENTION

Adequate antibiotic prophylaxis is essential in reducing the risk of prosthesis-associated infections^[10]. The objective of antimicrobial prophylaxis is to obtain serum and tissue drug levels that exceed the MICs for organisms that are likely to be a threat, for the entire duration of the operation. Systemic antibiotics should be administered just prior to the surgery. While administering prophylactic treatment, it is important to consider antibiotic resistance patterns associated with individual hospitals, as well as toxic and allergic reactions that may occur in patients undergoing surgery. In Orthopedic surgery, first- or second-generation cephalosporins such as cefazolin or cefuroxime are rational choices. However if the patient suffers from a β -lactam allergy, drugs like vancomycin, teicoplanin or clindamycin should be used^[3,8]. Recently, Qadir *et al*^[27] suggested Vancomycin to be used as a topical powder in the prevention of PJI. In settings where there is a high prevalence of MRSA, the use of glycopeptides is considered to be appropriate^[8].

From the moment of implantation, there is a constant risk of infection due to transient bacteraemia. Haematog-

enous seeding may occur at any point in the lifespan of a patient; however, the risk is significantly higher in the early stages following implantation. It is recommended to maintain good oral hygiene along with the regular removal of dental plaque to reduce the risk of bacteraemia. Also, if any dental, genitourinary tract or gastrointestinal tract procedure is to be undergone post implantation, a single dose of antibiotic prophylaxis should be utilized^[3,8].

CONCLUSION

Prosthetic Joint Infections are still considered to be a significant risk worldwide due to the high mortality risks and exponential costs associated with them. And although several strides have been made to improve their diagnosis and management, numerous obstacles are yet to be tackled. A multidisciplinary approach is potentially the best option in dealing with PJI, and should include the involvement of microbiologists, orthopedic specialists, clinicians, pathologists and radiologists in order to improve decision-making processes and ensure overall success.

REFERENCES

1. Darton T, Townsend R. Bone and Joint Infections. *Surgery* 2009; **28**: 95-100 [DOI: 10.1016/j.mpsur.2009.10.023]
2. Bames R, Chetter I. Infection in Prosthetic Material. *Surgery* 2012; **30**: 667-672. Available from: URL: <http://yadda.icm.edu.pl/yadda/element/bwmeta1.element.elsevier-49efc1ec-9863-355b-9204-b7c017197511>
3. Esposito S, Leone S. Prosthetic joint infections: microbiology, diagnosis, management and prevention. *Int J Antimicrob Agents* 2008; **32**: 287-293 [PMID: 18617373 DOI: 10.1016/j.ijantimicag.2008.03.010]
4. Leone S, Borrè S, Monforte Ad, Mordente G, Petrosillo N, Signore A, Venditti M, Viale P, Nicastrì E, Lauria FN, Carosi G, Moroni M, Ippolito G. Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. *Int J Infect Dis* 2010; **14** Suppl 4: S67-S77 [PMID: 20843721 DOI: 10.1016/j.ijid.2010.05.005]
5. Jafari SM, Casper DS, Restrepo C, Zmistowski B, Parvizi J, Sharkey PF. Periprosthetic joint infection: are patients with multiple prosthetic joints at risk? *J Arthroplasty* 2012; **27**: 877-880 [PMID: 22386611 DOI: 10.1016/j.arth.2012.01.002]
6. Rao N, Soxman GL. Prosthetic Joint Infections in the Elderly. *Oper Tech Orthop* 2002; **12**: 131-138. Available from: URL: <https://getinfo.de/app/PROSTHETIC-JOINT-INFECTI-ONS-IN-THE-ELDERLY/id/BLSE:RN142747351>
7. Grammatico-Guillon L, Baron S, Gettner S, Lecuyer AI, Gaborit C, Rosset P, Rusch E, Bernard L. Bone and joint infections in hospitalized patients in France, 2008: clinical and economic outcomes. *J Hosp Infect* 2012; **82**: 40-48 [PMID: 22738613 DOI: 10.1016/j.jhin.2012.04.025]
8. Zimmerli W. Infection and musculoskeletal conditions: Prosthetic-joint-associated infections. *Best Pract Res Clin Rheumatol* 2006; **20**: 1045-1063 [PMID: 17127196 DOI: 10.1016/j.17453674.2013.823589]
9. Islam G, Tomlinson J, Darton T, Townsend R. Bone and Joint Infections. *Surgery* 2013; **31**: 187-192 [DOI: 10.1016/j.mpsur.2013.01.016]
10. Philip B, Robinson E. Bone and Joint Infection. *Medicine* 2013; **41**: 719-722. Available from: URL: <http://yadda.icm.edu.pl/yadda/element/bwmeta1.element.elsevier-629f37ed-5554-36e8-a658-986abd02194f>
11. Lee J, Kang CI, Lee JH, Joung M, Moon S, Wi YM, Chung DR, Ha CW, Song JH, Peck KR. Risk factors for treatment

- failure in patients with prosthetic joint infections. *J Hosp Infect* 2010; **75**: 273-276 [PMID: 20635512]
- 12 **Tseng SW**, Chi CY, Chou CH, Wang YJ, Liao CH, Ho CM, Lin PC, Ho MW, Wang JH. Eight years experience in treatment of prosthetic joint infections at a teaching hospital in Central Taiwan. *J Microbiol Immunol Infect* 2012; **45**: 363-369 [PMID: 22578641 DOI: 10.1016/j.jmii.2011.12.014]
 - 13 **Moran E**, Masters S, Berendt AR, McLardy-Smith P, Byren I, Atkins BL. Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. *J Infect* 2007; **55**: 1-7 [PMID: 17343916]
 - 14 **Carrega G**, Bartolacci V, Burastero G, Finocchio GC, Ronca A, Riccio G. Prosthetic joint infections due to *Mycobacterium tuberculosis*: A report of 5 cases. *Int J Surg Case Rep* 2013; **4**: 178-181 [PMID: 23276761]
 - 15 **Société de Pathologie Infectieuse de Langue Française (SPILF)**; Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT); Groupe de Pathologie Infectieuse Pédiatrique (GPIP); Société Française d'Anesthésie et de Réanimation (SFAR); Société Française de Chirurgie Orthopédique et Traumatologique (SOFOT); Société Française d'Hygiène Hospitalière (SFHH); Société Française de Médecine Nucléaire (SFMN); Société Française de Médecine Physique et de Réadaptation (SOFMER); Société Française de Microbiologie (SFM); Société Française de Radiologie (SFR-Rad); Société Française de Rhumatologie (SFR-Rhu). Recommendations for bone and joint prosthetic device infections in clinical practice (prosthesis, implants, osteosynthesis). Société de Pathologie Infectieuse de Langue Française. *Med Mal Infect* 2010; **40**: 185-211 [PMID: 20303685 DOI: 10.1016/j.medmal.2009.12.009]
 - 16 **Choi HR**, Kwon YM, Freiberg AA, Nelson SB, Malchau H. Periprosthetic joint infection with negative culture results: clinical characteristics and treatment outcome. *J Arthroplasty* 2013; **28**: 899-903 [PMID: 23523496 DOI: 10.1016/j.arth.2012.10.022]
 - 17 **Bailey C**, Duckett S, Davies S, Townsend R, Stockley I. *Haemophilus parainfluenzae* prosthetic joint infection. The importance of accurate microbiological diagnosis and options for management. *J Infect* 2011; **63**: 474-476 [PMID: 21871487 DOI: 10.1016/j.jinf.2011.08.009]
 - 18 **Bjerke-Kroll BT**, Christ AB, McLawhorn AS, Sculco PK, Jules-Elysée KM, Sculco TP. Periprosthetic joint infections treated with two-stage revision over 14 years: an evolving microbiology profile. *J Arthroplasty* 2014; **29**: 877-882 [PMID: 24199997 DOI: 10.1016/j.arth.2013.09.053]
 - 19 **Gomez E**. Laboratory Diagnosis of Prosthetic Joint Infection, Part I. *Clin Microbiol News* 2011; **33**: 55-60 [DOI: 10.1016/j.clinmicnews.2011.03.004]
 - 20 **Gomez E**, Patel R. Laboratory Diagnosis of Prosthetic Joint Infection, Part II. *Clin Microbiol News* 2011; **33**: 63-70 [DOI: 10.1016/j.clinmicnews.2011.04.001]
 - 21 **Cobo J**, Lora-Tamayo J, Euba G, Jover-Sáenz A, Palomino J, del Toro MD, Rodríguez-Pardo D, Riera M, Ariza J. Linezolid in late-chronic prosthetic joint infection caused by gram-positive bacteria. *Diagn Microbiol Infect Dis* 2013; **76**: 93-98 [PMID: 23541692 DOI: 10.1016/j.diagmicrobio.2013.02.019]
 - 22 **Matthews CJ**. Bone and Joint Infections. *Medicine* 2014; **42**: 266-270 [DOI: 10.1016/j.mpm.2014.02.007]
 - 23 **Martel-Laferrère V**, Laflamme P, Ghannoum M, Fernandes J, Di Iorio D, Lavergne V. Treatment of prosthetic joint infections: validation of a surgical algorithm and proposal of a simplified alternative. *J Arthroplasty* 2013; **28**: 395-400 [PMID: 23151368 DOI: 10.1016/j.arth.2012.06.034]
 - 24 **Puhto AP**, Puhto TM, Niinimäki TT, Leppilahti JJ, Syrjälä HP. Two-stage revision for prosthetic joint infection: outcome and role of reimplantation microbiology in 107 cases. *J Arthroplasty* 2014; **29**: 1101-1104 [PMID: 24461248 DOI: 10.1016/j.arth.2013.12.027]
 - 25 **Tsai JC**, Sheng WH, Lo WY, Jiang CC, Chang SC. Clinical characteristics, microbiology, and outcomes of prosthetic joint infection in Taiwan. *J Microbiol Immunol Infect* 2013; Epub ahead of print [PMID: 24064293 DOI: 10.1016/j.jmii.2013.08.007]
 - 26 **Cabo J**, Euba G, Saborido A, González-Panisello M, Domínguez MA, Agulló JL, Murillo O, Verdager R, Ariza J. Clinical outcome and microbiological findings using antibiotic-loaded spacers in two-stage revision of prosthetic joint infections. *J Infect* 2011; **63**: 23-31 [PMID: 21596440 DOI: 10.1016/j.jinf.2011.04.014]
 - 27 **Qadir R**, Ochsner JL, Chimento GF, Meyer MS, Waddell B, Zavatsky JM. Establishing a role for vancomycin powder application for prosthetic joint infection prevention-results of a wear simulation study. *J Arthroplasty* 2014; **29**: 1449-1456 [PMID: 24636904 DOI: 10.1016/j.arth.2014.02.012]

P- Reviewer: Korovessis P, Schoenhagen P **S- Editor:** Ji FF
L- Editor: A **E- Editor:** Liu SQ



GENERAL INFORMATION

World Journal of Clinical Infectious Diseases (*World J Clin Infect Dis*, *WJCID*, online ISSN 2220-3176, DOI: 10.5495) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

Aims and scope

WJCID will focus on a broad spectrum of topics on infectious diseases that will cover epidemiology, immune-pathogenesis, genetic factors, host susceptibility to infection, vector control, novel approaches of treatment, molecular diagnostic and vaccines. It will provide a common stage to share the visions, new approaches, most advanced techniques, and to discuss research problems that will help everyone working in the field of various infections to exchange their views and to improve public health. *WJCID* will also focus on broad range of infections like opportunistic infections, zoonotic infections, tropical and neglected tropical diseases, emerging infections, *etc.* and following topics related to these issues: (1) Causative agents discussing various pathogens; (2) Vectors and Mode of transmission; (3) Host-pathogen interaction and immune-pathogenesis of the disease; (4) Epidemiology of the infection and vector control strategies; (5) Genetic factors covering both host and pathogen; (6) Molecular diagnostic techniques vaccines; and (7) Recent advances in cell tissue culture, lab techniques, *etc.* Various other related fields like medical microbiology, pharmacology of herbs, bioinformatics, *etc.* will be included.

We encourage authors to submit their manuscripts to *WJCID*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

WJCID is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 43 OA clinical medical journals, including 42 in English, has a total of 15471 editorial board members or peer reviewers, and is a world first-class publisher.

Columns

The columns in the issues of *WJCID* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endo-

scopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the forefront of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, *etc.*; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in clinical infectious diseases; (12) Research Report: To briefly report the novel and innovative findings in clinical infectious diseases; (13) Meta-Analysis: To summarize a given quantitative effect, e.g., the clinical effectiveness and safety of clinical treatments by combining data from two or more randomized controlled trials, thereby providing more precise and externally valid estimates than those which would stem from each individual dataset if analyzed separately from the others; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJCID*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of clinical infectious diseases; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

Name of journal

World Journal of Clinical Infectious Diseases

ISSN

ISSN 2220-3176 (online)

Instructions to authors

Launch date

December 30, 2011

Frequency

Quarterly

Editors-in-Chief

Shyam Sundar, MD, FRCP (London), FAMS, FNASc, FASc, FNA, Professor, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India

Lihua Xiao, DVM, PhD, Senior Scientist, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Bldg 23, Rm 9-168, MS D66, 1600 Clifton Rd, Atlanta, GA 30333, United States

Editorial office

Jin-Lei Wang, Director

Xiu-Xia Song, Vice Director

World Journal of Clinical Infectious Diseases

Room 903, Building D, Ocean International Center,

No. 62 Dongsihuan Zhonglu, Chaoyang District,

Beijing 100025, China

Telephone: +86-10-85381891

Fax: +86-10-85381893

E-mail: editorialoffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

Publisher

Baishideng Publishing Group Inc

8226 Regency Drive,

Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

Instructions to authors

Full instructions are available online at http://www.wjgnet.com/2220-3176/g_info_20100316155305.htm.

Indexed and Abstracted in

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

SPECIAL STATEMENT

All articles published in journals owned by the BPG represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJCID* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of BPG, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry

at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/2220-3176office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/2220-3176/g_info_20100722180909.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to bpoffice@wjgnet.com, or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be

provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomerybissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381892 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJCID*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$), and CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: http://www.wjgnet.com/2220-3176/g_info_20100725072755.htm.

Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>

Instructions to authors

www.wjgnet.com/1007-9327/13/4891.pdf; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a $P < 0.05$, ^b $P < 0.01$ should be noted ($P > 0.05$ should not be noted). If there are other series of P values, ^c $P < 0.05$ and ^d $P < 0.01$ are used. A third series of P values can be expressed as ^e $P < 0.05$ and ^f $P < 0.01$. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobao Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID: 2516377 DOI: 10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI: 10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI: 10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI: 10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI: 10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorffheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001

Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming, EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as *v* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5 μ g/L; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantums can be found at: http://www.wjgnet.com/2220-3176/g_info_20100725073806.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

Examples for paper writing

All types of articles' writing style and requirement will be found in the link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

RESUBMISSION OF THE REVISED MANUSCRIPTS

Authors must revise their manuscript carefully according to the revision policies of BPG. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade A certificate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to esps@wjgnet.com.

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/2220-3176/g_info_20100725073726.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/2220-3176/g_info_20100725073445.htm.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

STATEMENT ABOUT ANONYMOUS PUBLICATION OF THE PEER REVIEWERS' COMMENTS

In order to increase the quality of peer review, push authors to carefully revise their manuscripts based on the peer reviewers' comments, and promote academic interactions among peer reviewers, authors and readers, we decide to anonymously publish the reviewers' comments and author's responses at the same time the manuscript is published online.

PUBLICATION FEE

WJCID is an international, peer-reviewed, OA, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 698 USD per article. All invited articles are published free of charge.



Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

